Clinical Characteristics, Treatment Patterns, and Outcomes of Patients With Locally Advanced/Metastatic Hepatocellular Carcinoma Treated at the Veterans Health Administration.
Munaf A AlkadimiTamarah A AldawoodiKana T LuceroMaria E FierroLauren D BoyleMichael J MaderKathleen R FranklinSukeshi P AroraZohra NooruddinPublished in: The oncologist (2024)
In real world, despite having similar PFS as the phase III IMbrave 150 trial, our OS at 12 months was lower (52% vs. 67%) because our study included a higher proportion of elderly patients with moderate liver dysfunction and a 40% non-White. This study provided real-world outcomes that differed from the study population in a pivotal trial.
Keyphrases
- phase iii
- clinical trial
- squamous cell carcinoma
- healthcare
- public health
- open label
- type diabetes
- locally advanced
- study protocol
- small cell lung cancer
- randomized controlled trial
- oxidative stress
- radiation therapy
- skeletal muscle
- adipose tissue
- climate change
- weight loss
- newly diagnosed
- combination therapy
- glycemic control
- replacement therapy